valu usd unless otherwis note
view downgrad pti sector perform outperform
base mix data report today cf corrector
sign activ ph ii given lack clear benefit
believ work need done fulli de-risk asset
yet enough confid profil
construct share ultim succeed pti remain
rel uniqu multipl clinical-stag cftr modul
success could creat substanti valuat upsid
asset de-risk move sidelin lower target
decreas po
pti report ph ii data cftr corrector show sweat chlorid
improv neglig benefit ad patient
maintain orkambi significantli reduc sweat chlorid level
mg mg dose increas
non-significantli maximum mg dose
placebo-adjust patient mg dose group experienc
statist signific increas wt gain averag kg
believ potenti signal activ possibl
explan low improv sweat chlorid chang --
possibl cleanest marker cftr corrector activ -- show
continu declin day higher dose
improv per discuss suggest greater benefit
could observ longer trial safeti signal
indic pti could potenti dose higher subsequ studi
obtain greater effect extra-pulmonari effect observ area
like wt gain glucos improv increas could support
evid bronchoconstrict orkambi unmask
observ optim backbon like symdeko
might necessarili fair compar benefit
observ next-gen corrector top orkambi lastli given
potenti complementari mechan vs corrector bar
improv may lower
howev given result overal believ data
import fulli de-risk program placebo-adjust benefit
appear margin even exclud one patient
exacerb wherea corrector abl show much
clearer improv period
continu pg
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
base case assum probabl success
pti proprietari combin cystic fibrosi cf
market penetr homozyg het/
min patient believ would gener
out-year ww revenu price target deriv
blend dcf use discount rate
termin growth rate probability-adjust multipl
adjust ep discount analys
pti combin shown subsequ studi
competit efficaci benefit good safeti po estim
could increas near market penetr estiamt
could increas fair valu could base
blend dcf probability-adjust multipl
adjust ep
downsid scenario proprietari cftr combin
fail show efficaci benefit safeti signal emerg
reduc probabl success ctfr combin
reach market believ share pti could trade
approxim estim cash
pti one compani develop multipl clinical-
stage cftr modul treatment cf cftr
amplifi cftr corrector cftr
potenti potenti disease-
modifi treatment cf preclin studi indic
pti doublet triplet combin produc addit
effect cftr greater orkambi kalydeco
alon earli clinic data indic patient
alreadi stabl orkambi may benefit addit
treatment regimen clinic
result mix date balanc larg potenti
opportun proprietari triple-combo cf mani
shots-on-go individu modul approv
adjunct therapi current market combin
believ share current reflect fair valu pti potenti
posit larg commerci opportun
cf price point approv
therapi preclin studi indic pti doublet
triplet combin produc addit effect cftr
function greater orkambi kalydeco alon earli
studi indic pti cftr amplifi could benefit
patient alreadi stabl orkambi help valid activ
open potenti addit commerci
opportun clear regulatori path forward cf
individu compon pti tripl combo first test
top approv therapi move proprietari
risk pti cftr-modul test
small number cf patient promis early-stag data
may fail replic larger studi cftr-modul
compon develop adjunct therapi
already-approv cf treatment depend vrtx-
singl cftr-modul could push back timelin
proprietari triple-combo year even success
develop proprietari combin vrtx entrench
cf commun physician may difficult
potenti catalyst data doublet
combo cf patient initi
initi dose
cf patient
preliminari data cf patient
data combo studi
continu cover
exposur issu potenti ddi luma compon orkambi appear
respons disconnect level exceed higher dose sweat
chlorid dose-depend improv look less robust next-
gener corrector though acknowledg may tougher show add sweat chorid
improv top orkambi vs top symdeko lastli post-hoc analysi
elimin brochoconsctrict patient reflect real activ lung function
one must assum patient experienc acut bronchoconstrict soon orkambi dose
would truli blunt benefit addit drug chronic
exhibit pti potenti mileston pipelin
studi cf patient stabl data doublet cf mad studi cf dose cf data cf combo data combo fibrosi cftr amplifierphas fibrosi cftr correctorphas fibrosi cftr potentiatorphas ipti fibrosi cftr fibrosi cftr fibrosi cftr potentiatorpreclinicalmilestonespipelin exhibit pti incom statement
pti incom statement thousand except cf total revenu good research gener total oper loss interest income- interest incom expens incom loss incom tax provision- net incom incom loss due modif prefer net incom attribut common outstand share outstand proteostasi inc
price target deriv blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys price target support sector perform rate given limit
clinic data date increas develop risk believ specul risk qualifi
appropri
risk rate price target
pti treatment test small number cystic fibrosi patient
promis early-stag data may fail replic larger studi singl cftr-modul
compon develop adjunct therapi alreadi approv cf treatment
depend vrtx-own therapi may limit price power lack efficaci
safeti signal singl compon proprietari triple-combo could lead clinic
failur and/or delay even success develop proprietari combin vrtx
entrench cf commun physician may difficult overcom
proteostasi pti biopharmaceut compani primarili focus
develop cftr modulator-bas therapi cystic fibrosi cf compani
develop proprietari triple-combin therapi compos cftr amplifi corrector
potenti preclin data confirm three compon addit effect
cftr function combin well combin current
market cf therapi three compon enter clinic first trial
evalu tripl combin cf patient set initi first half
preliminari data expect end addit develop therapi
cf pti establish partnership agreement astella pharma conduct
preclin research discoveri unfold protein respons upr modul protein
conform diseas found pti headquart cambridg massachusett
